Forum Πρωτοβάθμιας Φροντίδας Υγείας
ΠΦΥ -Εκπαίδευση => Αποσπάσματα από τον έντυπο & ηλεκτρονικό τύπο => Μήνυμα ξεκίνησε από: Argirios Argiriou στις 2 Ιουλίου 2014, 00:34:15
-
L-dopa, το καταφρονεμένο Madopar, το οποίο καλά - καλά δεν το βρίσκουμε στα φαρμακεία στην Ελλάδα. ( Έχουμε φροντίσει να κατεβάσουμε την τιμή του τόσο πολύ ώστε να είναι συχνά σε έλλειψη).
Βέβαια πρέπει να τονίσουμε ότι η διάγνωση και η αρχική τουλάχιστον θεραπεία ασθενούς με Parkinson πρέπει να γίνεται από Νευρολόγο ( να προσέχουμε βέβαια σε ποιόν Νευρολόγο στέλνουμε τον ασθενή μας γιατί δεν αξίζουν όλοι στην Ελλάδα τον τίτλο τους).
June 20, 2014
The End of Levodopa Phobia?
Michael S. Okun, MD reviewing PD MED Collaborative Group. Lancet 2014 Jun 11. Lang AE and Marras C. Lancet 2014 Jun 11. Michael S.
An important update for clinicians treating patients with Parkinson disease Michael S. Okun, MDWhich medication should be used as first-line therapy for Parkinson disease (PD) has been an open and important question. To address this question, researchers conducted a pragmatic, open-label, randomized trial in patients with a new diagnosis of PD. The 1620 patients were randomized to receive a dopamine agonist (632 patients), a monoamine oxidase inhibitor (MAOBI; 460 patients), or levodopa (528 patients). Both patients and clinicians were aware of their treatment status. The primary outcome was the mobility dimension on the Parkinson's disease questionnaire (PDQ-39) quality-of-life scale.Median follow-up was 3 years. The average PDQ-39 mobility score over the first 7 years was 1.8 points better with levodopa than with the other two treatments, a significant difference. At 7 years, levodopa remained the best therapy, but there was a small difference favoring initial therapy with an MAOBI versus a dopamine agonist. A generic quality-of-life measure confirmed the study's major finding favoring levodopa therapy. Rates of dementia, admission to care institutions, and death were not significantly different among groups; however, the study was not designed to assess these outcomes. There were important differences in rates of discontinuation due to treatment-related side effects (28% with dopamine agonists, 23% with MAOBIs, 2% with levodopa).
Comment
These results will likely affect the clinical care of the PD patient, especially in the coming years. Over the past two decades, a trendy phenomenon referred to as levodopa phobia (intentionally avoiding prescriptions for levodopa) has affected both prescribing physicians and patients, largely in a negative way (Neurology 2005; 64:923). As editorialists note, this change in clinical practice was associated with aggressive pharmaceutical marketing. These new results suggest that all therapies have potentially beneficial effects in PD and that initiating early levodopa therapy can have short- and long-term benefits, as well as a tolerability advantage. The study did not adequately address whether patients younger than 70 would be more appropriate for levodopa-sparing strategies than older patients; this point should be explored in future studies. All three therapies should be considered and the choice of drugs should be tailored to the individual patient, although patient-rated mobility favors levodopa therapy, as does the risk for impulse control issues and other side effects.
Citation(s): PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): A large, open-label, pragmatic randomised trial. Lancet 2014 Jun 11; [e-pub ahead of print]. (http://dx.doi.org/10.1016/S0140-6736(14)60683-8) Lang AE and Marras C.Initiating dopaminergic treatment in Parkinson's disease. Lancet 2014 Jun 11; [e-pub ahead of print]. (http://dx.doi.org/10.1016/S0140-6736(14)60962-4)
- See more at: http://www.jwatch.org/na34945/2014/06/20/end-levodopa-phobia?query=most-popular-read#sthash.wIqXMsUE.dpuf
http://www.lakartidningen.se/Klinik-och-vetenskap/Nya-ron/2014/06/Borja-parkinsonbehandling-med-L-dopa/